Cocrystal Pharma, Inc.
COCP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.95
KIRA · Stoqly’s AI analyst, in plain words
- Cocrystal Pharma, Inc. lost $8.8M in fiscal 2025.
- Free cash flow was −$8.2M in fiscal 2025, — of revenue.
Market cap
$13.1M
P/E
—
Revenue
—
Net income
−$8.8M
Free cash flow
−$8.2M
Operating margin
—
Cocrystal Pharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cocrystal Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Cocrystal Pharma, Inc.
- CIK
- 0001412486
Cocrystal Pharma, Inc. · COCP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$14.2M | −$38.8M | −$18.0M | −$17.5M | −$8.8M |
| Diluted EPS | −$0.16 | −$4.77 | −$1.87 | −$1.72 | −$0.78 |
| Cash | |||||
| Cash from operations | −$12.7M | −$21.4M | −$14.7M | −$16.5M | −$8.2M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$12.8M | −$21.5M | −$14.8M | −$16.5M | −$8.2M |
| Share count change | 60.0% | −90.8% | 18.5% | 5.4% | 11.0% |
| Debt and strength | |||||
| Cash and short-term investments | $58.7M | $37.1M | $26.4M | $9.9M | $7.0M |
| Shareholders' equity | $77.5M | $39.6M | $26.4M | $9.5M | $6.3M |
| Current ratio | 38.4x | 33.0x | 8.9x | 4.8x | 3.7x |
| Interest coverage | −3,555.3x | −19,414.5x | — | — | — |
| Returns and quality | |||||
| Return on equity | −21.8% | −66.3% | −54.5% | −97.5% | −111.4% |
| Return on tangible equity | −24.3% | −98.1% | −68.2% | −183.8% | −139.5% |
| Altman Z'' | 37.1 | 8.7 | −25.8 | −82.7 | −115.2 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cocrystal Pharma, Inc. · COCP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.95 a share, the company is worth $13.1M.
Source: SEC EDGAR XBRL filings (CIK 0001412486). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.